Star Phoenix Group appoints Dr YuFeng Meng to its Board as Non-Executive Director

– UK, London –  Star Phoenix (LON: STA), an international company with an oilfield services business in Trinidad and an oil and gas interest in Indonesia, today announced the appointment of Dr. YuFeng Meng as a Non-Executive Director to the Board with immediate effect.

Dr YuFeng is the nominee of Beijing Sibo Investment Management LP, pursuant to the contractual right to appoint up to three Non-Executive Directors to the Board of the Company above 10% shareholding, arising from the subscription agreement entered into with the Company in 2015.

The Board welcomes Dr Meng to the Board of the Company and believes her experience and background will be invaluable as the Company progresses towards potential new business ventures.

About Dr Meng YuFeng

Dr. Meng’s career spans over 30 years across the US, Australia, Hong Kong, and China where she held various leadership, management and consulting roles in different sectors including education, aircraft tyre logistics, waste management, real estate, equity investment, banking and Free Trade Zone management and marketing. Dr. Meng has experience in the public sector, project management and finance (particularly in Build-operate-transfer (BOT) or build-own-operate-transfer (BOOT) project financing). More recently, she organized numerous government trade delegations to promote bilateral business cooperation between China and Australia.

Dr Meng holds a PhD in Business Administration from the InterAmerican University and an MBA in Business Administration from the Southern California University.

For more information: https://www.starphoenixgroup.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.